Skip to main content
Equibles
BCAB logo

BCAB · BioAtla, Inc. · Metrics

Track BCAB — free

Use BCAB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BCAB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.69 -0.05 (-2.59%) At close · Aug 31
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management's assessment concluded that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the issuance date of these condensed consolidated financial statements.”
View the 10-Q filed Aug 13, 2026
Market Cap
$2.89M
Shares
1.67M
Volume · Aug 31 130.29K Avg daily vol (3M) 80.45K

BCAB metrics

39 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.69
Market cap
$2.89M

Price action

20 metrics
Price change (1W)
-48.5%
Price change (30D)
—
Price change (3M)
-52.1%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
115.8%
Annualized volatility (3M)
116.0%
Beta
1.2
RSI (14D)
19.8
Price vs SMA 50
-51.6%
Price vs SMA 200
—
Avg volume (3M)
80,445
Relative volume
1.6
Average dollar volume
$251,867

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.67M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,088.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-13

Profitability

9 metrics
Gross margin
—
Operating margin
-32,146.7%
Trailing 12 months
Net margin
-31,800.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$32.12M
Net income (TTM)
−$31.45M
Trailing 12 months
Diluted EPS (TTM)
$-25.30
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-21.79

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+42.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-330.9%
Debt / equity
—
Current ratio
0.2
EBITDA (TTM)
−$31.93M
Free cash flow (TTM)
—
Quick ratio
0.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.54M
Latest balance sheet
Cash & equivalents
$1.54M
Total assets
$9.51M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$23.48M
Capital expenditures (TTM)
—
R&D (TTM)
$25.46M
SG&A (TTM)
—
Stock compensation (TTM)
$3.99M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
21
13F filer change QoQ
-15
Institutional ownership
17.7%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1826892 CUSIP 09077B203 Visit website Investor relations